Oncology
Sevabertinib Approved for Advanced Non-Squamous NSCLC
The FDA granted accelerated approval to sevabertinib for a biomarker-defined group of adults with locally advanced or metastatic non-squamous NSCLC. The exact label governs testing and treatment-line eligibility.
Rayan Salih · September 29, 2026 · 7 min